---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031280"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-09-28T11:00:14+00:00"
generated_at: "2026-10-12T13:29:50.994025+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Moleculin publishes peer-reviewed Annamycin cardiac safety analysis: no cardiotoxicity in 90 patients across 5 trials

## Summary
- Pooled analysis of 5 trials (3 AML, 2 metastatic STS): 90 patients treated, paired echocardiographic data for 78; mean LVEF 60.6% at baseline vs 60.0% post-treatment (p=0.84).
- No association between cumulative Annamycin dose or patient age and LVEF change; serial ECGs, troponin I/T and global longitudinal strain showed no treatment-related cardiotoxicity.
- Median cumulative Annamycin dose was 660 mg/m2, exceeding conventional anthracycline lifetime limits; analysis independently reviewed by a Cleveland Clinic cardio-oncology laboratory.
- CEO Walter Klemp said the absence of detectable cardiac toxicity beyond traditional dose thresholds supports continued development of Annamycin as a potentially safer anthracycline.
- Annamycin is currently being evaluated in Moleculin's MIRACLE clinical development program for relapsed or refractory AML.

## SEC filing metadata
- accession: 0001437749-26-031280
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-09-28T11:00:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/0001437749-26-031280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031280/mbrx20260925_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031280
- JSON: https://secwatch.observer/filing/0001437749-26-031280.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.